We are live on ! Find out more
AQST icon

Aquestive Therapeutics

190 hedge funds and large institutions have $357M invested in Aquestive Therapeutics in 2026 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 66 increasing their positions, 56 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more capital inflows, than outflows

Capital inflows: $47.5M | Capital outflows: $31.4M

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

37% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 19

18% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 56

3% more funds holding

Funds holding: 184 → 190 (+6)

2.74% more ownership

Funds ownership: 57.41% → 60.16% (+2.7%)

9% more call options, than puts

Call options by funds: $7.71M | Put options by funds: $7.06M

Holders
190
Holders Change
+6
Holders Change %
+3.26%
% of All Funds
2.31%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
26
Increased
66
Reduced
56
Closed
19
Calls
$7.71​M
Puts
$7.06​M
Net Calls
+$645​K
Net Calls Change
-⁠$5.47​M

AQST Hedge Fund Activity: Q3 2026 in Review

190 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2026, worth a combined $357M — up 19% from $300M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AQST positions and 19 closed out — a net gain of 7 holders — while 66 added to existing stakes and 56 trimmed.

The largest buyer was Rosalind Advisors, adding an estimated $7.78M. The largest seller was Propel Bio Management, cutting an estimated $5.17M.

  • 190 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2026, up from 184 in Q2 2026.
  • Funds reported $357M of Aquestive Therapeutics stock for Q3 2026, up 19% quarter-over-quarter.
  • 26 funds opened new Aquestive Therapeutics positions in Q3 2026 and 19 closed out, a net change of +7 holders.
  • The largest Aquestive Therapeutics buyer in Q3 2026 was Rosalind Advisors, an estimated $7.78M added.
  • The largest Aquestive Therapeutics seller in Q3 2026 was Propel Bio Management, an estimated $5.17M sold.

Based on aggregated 13F filings for Q3 2026.